Uchio Eiichi, Itoh Yuki, Kadonosono Kazuaki
Department of Ophthalmology, Fukuoka University School of Medicine, Fukuoka, Japan.
Ophthalmologica. 2007;221(3):153-8. doi: 10.1159/000099294.
BACKGROUND/AIMS: We evaluated the efficacy and safety of long-term management of patients with vernal keratoconjunctivitis (VKC) with bromfenac sodium eye drops in combination with corticosteroids and anti-allergic eye drops.
Twenty-two patients with VKC were randomly assigned to receive two test eye drops, either bromfenac sodium 0.1% (group A) or placebo eye drops (normal saline; group B) for a mean observation period of 20.9 months. Topical corticosteroids and mast cell stabilizers were continued during the observation period.
The mean 2-year recurrence rate was 90.9% in group A and 11.3% in group B, with a significant difference. No serious side effect was observed in group A.
These results suggest that bromfenac sodium eye drops can be used as baseline local treatment in patients with VKC.
背景/目的：我们评估了溴芬酸钠滴眼液联合皮质类固醇和抗过敏滴眼液对春季角结膜炎（VKC）患者的长期治疗效果及安全性。
22例VKC患者被随机分为两组，分别接受两种试验滴眼液，即0.1%溴芬酸钠滴眼液（A组）或安慰剂滴眼液（生理盐水；B组），平均观察期为20.9个月。观察期间持续使用局部皮质类固醇和肥大细胞稳定剂。
A组2年平均复发率为90.9%，B组为11.3%，两组间差异有统计学意义。A组未观察到严重副作用。
这些结果表明，溴芬酸钠滴眼液可作为VKC患者的基础局部治疗药物。
